Life Science Research Tools

July 15, 2016 | 60 Pages | SKU: IRTNTR9873

Outlook of the non-invasive prenatal testing (NIPT) market

Non-invasive prenatal testing (NIPT) is an advanced technology that helps determine fetal chromosomal anomalies by analyzing the fetus’ cell-free DNA. These procedures include both non-invasive techniques, such as serum screening and ultrasonography and invasive methods like amniocentesis and chorionic villus sampling. As the invasive procedures have a higher risk quotient, including the risk of fetal loss, most healthcare professionals prefer non-invasive techniques. NIPTs or non-invasive prenatal screening are new genetic tests that use cell-free circulating fetal DNA in the maternal serum to screen for more common fetal aneuploidies, such as trisomy 21, trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). With increased patient access to healthcare information as well as advertising, the NIPT market is anticipated to have a positive outlook in the coming years. Gynecologists should be able to provide accurate information regarding NIPTs, their appropriateness and limitations, and specialist referral and follow-up. The global non-invasive prenatal testing market is anticipated to witness tremendous growth and will post an impressive CAGR of close to 18% over the forecast period.

According to the market research analysts, the vendors are increasingly entering into partnerships and collaborations to extend their product offerings, increase their market shares, and expand their operations. These partnerships and collaborations help vendors enhance their R&D capabilities for manufacturing innovative devices that meet consumer needs. For instance, in 2015, Human Longevity entered into a

June 17, 2016 | 70 Pages | SKU: IRTNTR9692

Overview of the cardiopulmonary stress testing systems market

According to the market research analysts at Technavio, the cardiopulmonary stress testing systems market will witness steady growth and will post a CAGR of more than 8% over the forecast period. With increasing focus on preventive diagnosis, the market for cardiopulmonary stress testing systems is expected to have a positive outlook in the coming years. In 2014, the American Heart Association estimated that cardiovascular disease-related deaths accounted for nearly 35% of the overall deaths worldwide. Awareness of these diseases and educating the public and users can help in early diagnosis, reducing the chances of developing heart diseases. For instance, the Heart Truth is a national educational program for females in the US that raises awareness about cardiac diseases and their risk factors. This program helps educate and motivate women to take necessary preventive action against the disease. Moreover, various research studies have estimated that early detection of cardiovascular diseases can help decrease the number of deaths. For example, a research study estimated that during 2001-2011, the mortality rate due to cardiopulmonary diseases declined about 39% due to early detection. Such positive results are anticipated to encourage people to undergo cardiopulmonary exercise testing to prevent future complications.

One of the significant trends bolstering this market’s growth prospects, is the increasing number of private cardiac specialty hospitals around the world. Governments of various countries are facilitating both private and community hospitals to increase the number of cardiac surgeries. Coronary artery bypass graft (CABG) surgery is one of the most frequently

June 09, 2016 | 75 Pages | SKU: IRTNTR9689

Outlook of the autoimmune disease diagnostics market

The global autoimmune disease diagnostics market is projected to witness fast-paced growth and will post an impressive CAGR of more than 6% over the forecast period. The recent advances in genomics and proteomics have accelerated biomedical research, leading to the development of novel biomarkers. Biomarkers are biochemical entities that serve as an indicator for a disease. Biomarkers linked to autoimmune diseases are being discovered and studied, which have led to the development of biomarker-specific new diagnostic products. These significant factors will drive this market’s growth in the coming years.

With increasing focus on companion diagnostic tests, the market for autoimmune disease diagnostics has a positive outlook over the next four years. Companion diagnostics help in the screening of individuals or groups who are likely to respond better to a therapeutic agent. The development of a companion diagnostic test for an autoimmune disease involves the use of a diagnostic test and monitoring of disease prognosis in individuals undergoing therapy. These tests offer insights into the therapeutic regimen's positive impact on these individuals regarding the reduction in the activity of autoimmune diseases. Several vendors are looking to tap the companion diagnostic tests market for autoimmune diseases. For instance, Crescendo Bioscience, a subsidiary of Myriad Genetics, has developed VectraDA test for detecting multi-markers for rheumatoid arthritis

June 03, 2016 | 64 Pages | SKU: IRTNTR9068

Overview of the DNA sequencing products market

Technavio’s market research analyst predicts the global DNA sequencing products market to grow stupendously at an impressive CAGR of close to 19% over the forecast period. The declining costs of DNA sequencing is likely to contribute to the growth of this market in the coming years. The Human Genome Project was the first joint initiative of various organizations to map the human genome involved over 200,000 scientists and researchers. The research scientists used the Sanger method for DNA sequencing, and it took nearly 13 years for its completion and cost USD 3 billion. Since the project’s completion, DNA sequencing technologies have undergone major transformations over the years. Scientists are using new-age technologies, such as Illumina sequencing and 454 sequencing methods for genome mapping, which costs less and takes a shorter duration for completion. Moreover, a significant reduction in sequencing costs has led many countries to invest in research and development and offer cost-effective solutions whole genome sequencing, de novo sequencing, and accurate disease diagnosis.

In this market study report, the analysts have estimated factors such as rapid advancements in personalized medicine to propel the growth prospects of this market over the predicted period. Many medical facilities in developed and developing countries are increasingly offering DNA sequencing-based medical treatment. These facilities use sophisticated technologies and tools such as rapid DNA sequencer for large-scale and quantitative assessments of genomic sequences. Moreover, DNA sequencing devices have also helped in making important research discoveries in biomedical sciences. Also, genomic testing technologies assist in identifying oncogenic variants in tumor tissues and check the responsiveness of specific drugs. This allows physicians to develop a personalized treatment program

May 05, 2016 | 65 Pages | SKU: IRTNTR7946

Market outlook of the clinical immunoassay analyzer market in the US

Technavio’s market research analyst predicts the clinical immunoassay analyzer market in the US to grow at a healthy CAGR of around 6% during the forecast period. The patients’ growing demand for high-throughput screening with the aid of immunoassays is a significant factor that augments growth in this market during the forecast period.

In this market research report, analysts estimate eminent factors, such as the rising demand for next-generation immunodiagnostics, to drive market growth during the forecast period. These immunodiagnostic devices address the needs of modern clinical laboratories and provide high quality, reliable test results for patients and clinicians. The ability of such devices to improve the workflow and turnaround time for tests is envisaged to impel market growth during the forecast period.

Competitive landscape and key vendors

This market is characterized by the presence of intense competition among several large, medium, and small-sized manufacturers. These vendors form partnerships and provide premium-priced products to maintain their market share. However, since the local vendors in this market offer products at lower prices, they can be a serious threat to large companies.

The top vendors in the market are -

  • Abbott Diagnostics
  • Beckman Coulter
  • bioMerieux
  • Roche Diagnostics
  • Siemens Healthcare Diagnostic

Other prominent vendors in the market include Affimetrix, Boditech Med, DiaSorin, DRG International, Enzo Life Sciences, EMD Millipore, Immunodiagnostics System, Inova Diagnostics, Meso Scale Discovery, Nova Century Scientific, Olympus, Quidel, Radiometer, Randox Laboratories, SDIX, Tecan, and Thermo Fisher Scientific.

Application-based segmentation of the

February 10, 2016 | 52 Pages | SKU: IRTNTR8694

Overview of the global cochlear implants market

Technavio’s market research analyst has estimated the global market for cochlear implants to grow at an impressive CAGR of more than 14% by 2020. The advent of favorable government initiatives and reimbursement policies in emerging countries will aid in the growth of this market during the forecast period. Also, factors such as the rapid increase in geriatric population and the recent rise in the prevalence of acquired hearing loss will also foster the prospects for growth in this market until 2020.

The recent rise in product customization is the key driver for this market. Most of the leading cochlear implant device manufacturers are customizing their products in a bid to attract more consumers. Recently, it has been observed that numerous vendors are addressing the needs of the older population by developing products that increase the quality of digital sound. The advent of such aesthetically appealing cochlear implants will, in turn, augment the vendors’ growth potential by increasing their product sales.

Geographical segmentation of the cochlear implants market

  • Americas
  • APAC
  • EMEA

In terms of geography, the global cochlear implants market was dominated by the Americas, which accounted for more than 42% of the total market share during 2015. In the Americas, the US was the largest revenue contributor as it accounted for a significant share of the global market. Factors such as the presence of favorable reimbursement policies in this region and the high buying power of the populace in North America will spur the prospects for market growth in this region.

Competitive landscape and key vendors

The global cochlear implants market offers a moderate opportunity for vendors to grow during the